Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors-Reference-Cited by-同舟云学术

Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors

Published:2012-02 Issue:2 Volume:53 Page:178-180
ISSN:1386-6532
Container-title:Journal of Clinical Virology
language:en
Short-container-title:Journal of Clinical Virology

Author:

Colson Philippe,Purgus Raj,Borentain Patrick,Gérolami René

Publisher

Elsevier BV

Subject

Infectious Diseases,Virology

Reference5 articles.

1. Resistance to direct antiviral agents in patients with hepatitis C virus infection;Sarrazin;Gastroenterology,2010

2. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects;Bartels;J Infect Dis,2008

3. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates;López-Labrador;Antivir Ther,2008

4. Two years’ persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy;Colson;J Infect Dis,2011

5. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel;Thompson;JAMA,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study;HIV Clinical Trials;2016-02-11

2. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France;Journal of Medical Virology;2015-06-12

3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France;Journal of Medical Virology;2014-07-23

4. A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy;Antiviral Therapy;2013

5. HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors;PLoS ONE;2012-07-06